Company intelligence / Profile preview

Calimmune

Tucson, Arizona, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Calimmune developed ex vivo HSC gene therapies targeting chronic and incurable diseases such as HIV/AIDS, sickle cell disease, and β-thalassemia. Its lead program for HIV reached Phase I/II with encouraging safety data; the sickle cell/β-thalassemia candidate was in preclinical development at the time of acquisition by CSL Behring. Proprietary platforms aimed to improve manufacturing consistency and therapeutic efficacy.

Therapeutic areas: HematologyInfectious Diseases
Modalities: Ex vivo gene therapyHematopoietic stem cell (HSC) gene therapyCell-based therapies
Industry: Biotech

Drug pipeline

1 asset

CAL-H

Pre-clinical

Indications: Sickle cell disease, β-thalassemia

Partnerships

California Institute for Regenerative Medicine (CIRM)—funded clinical trials for the company’s lead HIV program

Beyond the preview

Go deeper on Calimmune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calimmune.

Explore the full profile